Ocrelizumab Subcut – Overcoming Barriers to Access – Pharmac Opens Consultation for Funding
After strongly advocating to Pharmac since July 2024, Multiple Sclerosis NZ welcomes the announcement today that Pharmac is opening public consultation for the funding of subcutaneous Ocrelizumab (Ocrevus). This funding comes as part of a multi-medicine deal between Pharmac and Roche. Ocrevus Subcutaneous (SC) is delivered by injection under the skin rather than by intravenous […]
Major announcement: Pharmac Initiates Consultation to fund Ocrelizumab for Primary Progressive MS.
Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to delay time to wheelchair by 7 years allowing people to continue working, supporting their families […]